Neos Therapeutics Inc. (NASDAQ:NEOS)’s share price rose 6.5% on Wednesday . The stock traded as high as $9.16 and last traded at $9.16, with a volume of 57,969 shares trading hands. The stock had previously closed at $8.60.

NEOS has been the subject of several research analyst reports. Wells Fargo & Co. reaffirmed a “buy” rating on shares of Neos Therapeutics in a research note on Wednesday, May 18th. Zacks Investment Research raised Neos Therapeutics from a “hold” rating to a “buy” rating and set a $11.00 price objective for the company in a research note on Thursday, April 21st. BMO Capital Markets assumed coverage on Neos Therapeutics in a research note on Tuesday, June 28th. They issued an “outperform” rating and a $15.00 price objective for the company. Finally, Royal Bank Of Canada dropped their price target on Neos Therapeutics from $33.00 to $29.00 and set an “outperform” rating for the company in a research report on Tuesday, May 17th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $21.75.

The firm has a 50-day moving average of $9.33 and a 200-day moving average of $9.80. The company’s market capitalization is $146.17 million.

Neos Therapeutics (NASDAQ:NEOS) last posted its earnings results on Monday, May 16th. The company reported ($0.79) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.87) by $0.08. On average, analysts forecast that Neos Therapeutics Inc. will post ($4.88) EPS for the current fiscal year.

In other Neos Therapeutics news, Director Alan L. Heller acquired 10,000 shares of Neos Therapeutics stock in a transaction dated Thursday, May 19th. The stock was acquired at an average cost of $7.61 per share, for a total transaction of $76,100.00. Following the completion of the transaction, the director now owns 379,888 shares in the company, valued at approximately $2,890,947.68. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Gregory J. Robitaille acquired 7,442 shares of Neos Therapeutics stock in a transaction dated Wednesday, May 18th. The shares were acquired at an average price of $7.55 per share, with a total value of $56,187.10. Following the completion of the transaction, the director now owns 55,677 shares of the company’s stock, valued at approximately $420,361.35. The disclosure for this purchase can be found here.

An institutional investor recently raised its position in Neos Therapeutics stock. Marshall Wace LLP raised its stake in Neos Therapeutics Inc. (NASDAQ:NEOS) by 11.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 96,162 shares of the company’s stock after buying an additional 9,929 shares during the period. Marshall Wace LLP owned about 0.60% of Neos Therapeutics worth $1,377,000 as of its most recent SEC filing.

Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.